An Approach to Disulfide Synthesis Promoted by Sulfonyl Chloride in Sodium Bicarbonate Aqueous Media
摘要:
A mild and efficient protocol for the synthesis of disulfides in aqueous media using mercaptans promoted by sulfonyl chloride is reported. This reaction offers the advantages of mild reaction conditions, short reaction time, high yields, and simple operation.
[EN] METHODS FOR PRODUCING ARYLSULFUR PENTAFLUORIDES<br/>[FR] PROCÉDÉS DE PRODUCTION DE PENTAFLUORURES DE SOUFRE ARYLÉS
申请人:IM & T RES INC
公开号:WO2010014665A1
公开(公告)日:2010-02-04
Novel methods for preparing arylsulfur pentafluorides are disclosed. Arylsulfur halotetrafluoride is reacted with a fluoride source under hydrous conditions to form an arylsulfur pentafluoride. The purification method is also disclosed.
Novel processes for preparing arylsulfur pentafluorides are disclosed. Processes include reacting at least one aryl sulfur compound with a halogen and a fluoro salt to form an arylsulfur halotetrafluoride. The arylsulfur halotetrafluoride is reacted with a fluoride source to form a target arylsulfur pentafluoride.
Iodine-promoted stereoselective amidosulfenylation of electron-deficient alkynes
作者:Fuhong Xiao、Dahan Wang、Shanshan Yuan、Huawen Huang、Guo-Jun Deng
DOI:10.1039/c8ra04374d
日期:——
Iodine-promoted three-component synthesis of substituted β-amino sulfides has been developed starting from a propargyl ester, aliphatic secondary amine, and disulfide. This protocol provides a step-economic and highlyregioselective entry to trisubstituted olefins with good substrate scope and functional group tolerance.
A method of treating pathological blushing is disclosed wherein the patient is administered a DP receptor antagonist. Compositions containing DP antagonists are also included.
揭示了一种治疗病理性面红的方法,其中患者接受DP受体拮抗剂。还包括含有DP拮抗剂的组合物。
Method of treating atherosclerosis, dyslipidemias and related conditions
申请人:——
公开号:US20040229844A1
公开(公告)日:2004-11-18
A method of treating atherosclerosis is disclosed wherein nicotinic acid or another nicotinic acid receptor agonist is administered to the patient in combination with a DP receptor antagonist. The DP receptor antagonist is administered to reduce, prevent or eliminate flushing that may otherwise occur.